Ivermectin: A Novel Method of Treatment of Nasal and Nasopharyngeal Myiasis

  • Abu Sayeed
  • Aftab AhmedEmail author
  • S. C. Sharma
  • S. A. Hasan
Original Article


To evaluate the efficacy of oral Ivermectin, in patients suffering from nasal and nasopharyngeal myiasis. This was a prospective study, comprising 80 patients of nasal and nasopharyngeal myiasis. Patients underwent clinical examination and nasal endoscopy at the time of presentation and findings were recorded. The patients were randomly divided in two groups. In group-I the patients underwent manual extraction of the maggots after instillation of chloroform and turpentine oil mixture, whereas the group-II patients underwent manual extraction with administration of two doses (24 h apart) of oral Ivermectin (6 mg each). The patients were instructed to record the time when they noticed shedding of maggots, and evaluated for the clearance of maggots by endoscopy after 24, 48 h and 7 days after the initial examination. The mean maggot shedding time (by t test) in Group-I was 41.23 ± 4.23 h and in Group-II was 24.60 ± 3.15 h. The difference being highly significant statistically, (p = 0.0001). The endoscopic clearance of maggots (by Chi square test) between the two group of patients was also statistically significant at 24 and 48 h with p value of (p = 0.002) and (p = 0.006) respectively. Oral Ivermectin was effective in treating nasal and nasopharyngeal myiasis, in terms of early clearance, decreased morbidity and less hospital stay. We conclude that oral Ivermectin can be used as a safe and effective method for the treatment of nasal & nasopharyngeal myiasis.


Nasopharyngeal myiasis Nasal myiasis Ivermectin Ivermectin in nasal myiasis 


Compliance with Ethical Standards

Conflict of interest

The Author declares that they have no conflict of interest.

Statement of Human Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Introduction to myiasis: natural history museum. Retrieved 11 May 2013Google Scholar
  2. 2.
    Sherman RA, Hall MJR, Thomas S (2000) Medicinal Maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol 45:55–81. CrossRefPubMedGoogle Scholar
  3. 3.
    Chigusa Y, Matsumoto J, Kirinoki M, Kawai S, Matsuda H, Oikawa A, Sato T (1998) A case of wound myiasis due to Lucilia sericata (Diptera: Calliphoridae) in a patient suffering from alcoholism and mental deterioration. Med Entomol Zool 49:125–127CrossRefGoogle Scholar
  4. 4.
    Ramli R, Rahman AR (2002) Oral myiasis: case report. Malays J Med Sci 9:47–50PubMedPubMedCentralGoogle Scholar
  5. 5.
    Baskaran M, Jagan Kumar B (2007) Geeverghese amritha. Cutaneous myiasis of face. J Oral Maxillofac Pathol 11:70–72CrossRefGoogle Scholar
  6. 6.
    Harwood RF, James MT (1969) Entomology in human and animal health. Macmillan, New York, p 548Google Scholar
  7. 7.
    Zumpt F (1965) Myiasis in man and animals in the old world. Butterworths, London, p 267Google Scholar
  8. 8.
    Zumpt F (1951) Myiasis in man and animals in Africa. S Afr J Clin Sci 2(1):38–69PubMedGoogle Scholar
  9. 9.
    James MT (1947) The flies that cause myiasis in man. Department of Agriculture, Misc, Publication No. 63, Washington, USAGoogle Scholar
  10. 10.
    Fisher MH, Mrozik H (1992) The chemistry and pharmacology of avermectins. Annu Rev Pharmacol Toxicol 32:537–553. CrossRefPubMedGoogle Scholar
  11. 11.
    Soni NK (2000) Endoscopy in nasal myiasis. Trop Dr 30(4):225–227CrossRefGoogle Scholar
  12. 12.
    Arena JP, Liu KK, Paress PS et al (1995) The mechanism of action of avermectins in Caenorhabditis elegance: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity. J Parasitol 81:286–294 [PMID: 7707209] CrossRefGoogle Scholar
  13. 13.
    Sahay LK (1959) A study of maggots and their otolaryngeal manifestations. Indian J Otolaryngol 11:146–168Google Scholar
  14. 14.
    Bowser C, Rieder A (2001) Detection of progesterone receptors in connective tissue cells of the lower nasal turbinates in women. Laryngorhinootologie 80:182–186CrossRefGoogle Scholar
  15. 15.
    Bunnag C, Jareoncharsri P, Tansuriyawong P, Bhothisuwan W, Chantarakul N (1999) Characteristics of atrophic rhinitis in Thai patients at the Siriraj Hospital. Rhinology 37(3):125–130PubMedGoogle Scholar
  16. 16.
    Kumar GV, Sowmya G, Shivananda S (2011) Chrysomyia bezziana oral myiasis. J Global Infect Dis 3:393–395CrossRefGoogle Scholar
  17. 17.
    Sharma H, Dayal D, Agarwal SP (1989) Nasal myiasis: review of 10 years experience. J Laryngol Otol 103(5):489–491CrossRefGoogle Scholar
  18. 18.
    CDC (2012) Increasing prevalence of diagnosed diabetes-United States and Puerto Rico 1995–2010. MMWR 61(45):918–921Google Scholar
  19. 19.
    CDC. Diabetes data and trends. Atlanta, GA: US Department of Health and Human Services, CDC, National Diabetes Surveillance System. Accessed 8 Nov 2012
  20. 20.
    Geiss LS, Cowie C (2011) Type 2 diabetes and persons at high risk of diabetes. In: Venkat Narayan KM, Williams D, Gregg EW, Cowie C (eds) Diabetes public health: from data to policy. Oxford University Press, New York, pp 15–32Google Scholar
  21. 21.
    Sharma H, Dayal D, Agrawal SP (1989) Nasal myiasis: review of 10 years experience. J Laryngol Otol 103:489–491CrossRefGoogle Scholar
  22. 22.
    Lui PC, Lee MK, Wong JH, Leung CY, Lee CK, Lai RW, Lam ET, Yeung JC, Suen DT, Tse GM (2005) Myiasis by chrysomya bezziana in surgical pathology. Pathology 37(1):80–82CrossRefGoogle Scholar
  23. 23.
    Victoria J, Trujillo R, Barreto M (1999) Myiasis: a successful treatment with topical ivermectin. Int J Dermatol 38(2):142–144CrossRefGoogle Scholar
  24. 24.
    De Tarso P, Pierre-Filho P, Minguini N, Pierre LM, Pierre AM (2004) Use of ivermectin in the treatment of orbital myiasis caused by Cochliomyia hominivorax. Scand J Infect Dis 36(6–7):503–505PubMedGoogle Scholar
  25. 25.
    Olsen RW, Snowman AM (1985) Avermectin B1a modulation of gamma aminobutyric acid/benzodiazepine receptor binding in mammalian brain. J Neurochem 44:1074–1082CrossRefGoogle Scholar
  26. 26.
    Pong SS, Wang CC (1980) The specificity of high affinity binding of avermectin B1a to mammalian brain. Neuropharmacology 19:311–317CrossRefGoogle Scholar
  27. 27.
    Sieghart W (1995) Structure and pharmacology of gamma aminobutyric acid-A receptor subtypes. Pharmacol Rev 47:181–231PubMedGoogle Scholar
  28. 28.
    Bennet DG (1986) Clinical pharmacology of ivermectin. JAVMA 189:100–103Google Scholar

Copyright information

© Association of Otolaryngologists of India 2018

Authors and Affiliations

  1. 1.Department of Otorhinolaryngology, Jawaharlal Nehru Medical CollegeAligarh Muslim UniversityAligarhIndia

Personalised recommendations